Cariprazine for Social Anxiety Disorder
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests Vraylar® to see if it can help people with social anxiety disorder by balancing brain chemicals related to mood and anxiety. Current treatments are not effective for everyone and often have side effects, so new options are needed.
Will I have to stop taking my current medications?
Yes, you will need to stop taking certain medications before joining the trial. Specifically, you cannot take fluoxetine within 28 days of starting, and you must stop taking other psychotropic medications like SSRIs, SNRIs, and benzodiazepines at least 14 days before the trial begins.
How does the drug Cariprazine differ from other drugs for social anxiety disorder?
Cariprazine is unique because it is primarily used as an antipsychotic for conditions like schizophrenia and bipolar disorder, and its use for social anxiety disorder is novel. Unlike traditional treatments for social anxiety, which often include antidepressants or benzodiazepines, Cariprazine works by targeting dopamine receptors, which may offer a different approach to managing symptoms.12345
Who Is on the Research Team?
Michael R Liebowitz, MD
Principal Investigator
Managing Director
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Cariprazine or placebo for Social Anxiety Disorder in a double-blind, placebo-controlled trial
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cariprazine
- Placebo
Cariprazine is already approved in United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Medical Research Network
Lead Sponsor
AbbVie
Industry Sponsor
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois